A BRCA1 and BRCA2 genetic test looks for inherited or tumor-acquired changes in two genes that repair damaged DNA. A germline pathogenic variant can raise lifetime risks for breast, ovarian, fallopian tube, primary peritoneal, prostate, pancreatic, and male breast cancer. The exact pattern differs between BRCA1 and BRCA2 and varies by sex, age, family history, and the specific variant.
Testing may use blood or saliva to evaluate inherited risk, or tumor tissue and circulating tumor DNA to guide cancer treatment. A tumor result does not always show whether a change is inherited, so confirmatory germline testing may be needed. Results are usually classified as pathogenic, likely pathogenic, uncertain, likely benign, or benign. A variant of uncertain significance should not be used for risk-reducing surgery or predictive testing in relatives. A negative result can be truly reassuring when a known family variant is absent, but may be uninformative when no affected relative has been tested.
- A germline pathogenic BRCA1 or BRCA2 variant is inherited in an autosomal dominant pattern, giving each child a 50% chance of inheriting it.
- BRCA1 commonly raises breast and ovarian cancer risk; BRCA2 also has stronger links to male breast, prostate, and pancreatic cancer.
- A VUS is not a positive result and should not change medical management by itself.
- A negative test is most informative when the laboratory specifically looked for a known family variant.
- Tumor-only BRCA results may require blood or saliva testing to determine whether the variant is inherited.
Table of Contents
- What BRCA1 and BRCA2 Do
- Who May Benefit From Testing
- Germline and Tumor Testing Methods
- How to Interpret Test Results
- Cancer Risks From Pathogenic Variants
- Screening and Risk Reduction
- Treatment Implications
- Family Testing, Reproductive Options, and Limitations
What BRCA1 and BRCA2 Do
BRCA1 and BRCA2 are tumor-suppressor genes. Their proteins help repair double-strand DNA breaks through homologous recombination, a high-accuracy repair process. A person with an inherited pathogenic variant starts life with one altered copy in every cell. If a susceptible cell later loses or disables the remaining working copy, DNA damage can accumulate and cancer may develop.
Having a pathogenic variant is a predisposition, not a diagnosis. Penetrance is incomplete, meaning not every carrier develops cancer. Risk also changes with age and is influenced by reproductive history, family history, lifestyle, screening, risk-reducing surgery, and other genetic modifiers.
BRCA1-associated breast cancers are more likely to be triple-negative, lacking estrogen receptor, progesterone receptor, and HER2. BRCA2-associated breast cancers are often hormone-receptor positive. These are tendencies, not rules. Either gene can be associated with different tumor subtypes.
The inherited condition is often called hereditary breast and ovarian cancer syndrome, although the name understates the importance of prostate, pancreatic, and male breast cancer. Ovarian risk includes epithelial cancers of the ovary, fallopian tube, and primary peritoneum because these diseases share biology and prevention strategies.
Most people with one pathogenic variant are healthy at birth and have no distinctive physical features. Very rare children who inherit pathogenic variants in both copies of BRCA2, or certain combinations involving both BRCA1 copies, can develop Fanconi anemia, a recessive disorder with developmental abnormalities, bone-marrow failure, and early cancers. This is different from the usual adult autosomal dominant cancer predisposition.
A BRCA variant can be inherited from the mother or father. Family histories may appear deceptively quiet when the family is small, relatives died young, there are few women on one side, or male-associated cancers were not recognized as part of the syndrome. Paternal history is just as relevant as maternal history.
A dominant inheritance result means each pregnancy has an independent 50% chance of passing on the familial variant. It does not mean half of the children in every family will inherit it, and it does not predict who will develop cancer.
Who May Benefit From Testing
Testing criteria have broadened because results can affect both treatment and prevention. Current professional guidance recommends offering BRCA1/2 testing to all people newly diagnosed with breast cancer at age 65 or younger and to selected older patients based on tumor features, ancestry, family history, sex assigned at birth, or treatment eligibility. Local criteria and insurance coverage vary.
Common reasons for germline evaluation include:
- Breast cancer at a young age
- Triple-negative breast cancer
- Male breast cancer
- Epithelial ovarian, fallopian tube, or primary peritoneal cancer
- Pancreatic cancer
- Metastatic, high-risk, or very-high-risk prostate cancer
- Bilateral breast cancer or multiple primary cancers
- A relative with a known BRCA1 or BRCA2 pathogenic variant
- Several relatives with breast, ovarian, pancreatic, or aggressive prostate cancer
- Ashkenazi Jewish or another ancestry with recognized founder variants, especially with relevant cancer history
- A tumor BRCA result that may be germline
- A calculated probability of hereditary cancer above a guideline threshold
Testing an affected relative first is usually most informative. If the family’s cancers are strongly suggestive but the person tested has never had cancer, a negative result may not reveal whether the family carries a variant that the unaffected person simply did not inherit or whether another gene is involved.
Many families are better served by a multigene hereditary-cancer panel than by BRCA1/2 alone. PALB2, TP53, PTEN, CDH1, ATM, CHEK2, RAD51C, RAD51D, BRIP1, mismatch-repair genes, and others can produce overlapping histories. A multigene panel increases diagnostic breadth but also increases the chance of uncertain findings and moderate-risk results that require nuanced management.
Pretest counseling should cover possible results, medical implications, family communication, privacy, insurance or employment protections in the person’s country, emotional effects, and cost. In the United States, federal protections do not cover life, disability, or long-term-care insurance in the same way they cover health insurance and employment.
Testing is generally not performed in children for adult-onset BRCA risk because screening does not begin in childhood. An adult who carries a familial variant can share information with children when they are mature enough to consider testing before screening age, often in early adulthood.
Germline and Tumor Testing Methods
Germline testing
Blood is the most common germline specimen. Saliva or cheek swabs are alternatives, though blood may be preferred after a failed saliva sample or when recent eating, smoking, or contamination affects quality. The laboratory sequences BRCA1 and BRCA2 and performs deletion/duplication analysis because pathogenic variants can involve one or more exons, not only small spelling changes.
If a family variant is already known, targeted testing for that exact change is usually sufficient and less expensive. The report should confirm the gene, transcript, DNA notation, protein notation, and classification.
Blood can occasionally be misleading after an allogeneic stem-cell transplant because circulating blood cells may carry the donor’s DNA. Active blood cancers and age-related clonal hematopoiesis can also complicate some germline results. A genetics team may use cultured skin fibroblasts or another non-blood tissue when necessary.
Tumor testing
Tumor sequencing may find BRCA1 or BRCA2 alterations that help select therapy. The change may be inherited, acquired only in the tumor, or present with loss of the second copy. Tumor-only testing cannot always distinguish these possibilities. An allele fraction near 50% is not proof of germline origin because tumor purity and copy-number changes affect the number.
A pathogenic tumor finding should be reviewed for germline confirmation according to the variant, cancer type, age, and personal and family history. Conversely, a negative tumor panel does not replace a validated germline test; coverage and deletion detection may differ.
Paired tumor-normal sequencing analyzes tumor and non-tumor DNA together. It can classify variants more accurately as somatic or germline and clarify loss of heterozygosity. Patients should know whether the service will report inherited findings and which genes are included.
Functional tumor biomarkers
Some cancers are tested for homologous recombination deficiency, genomic scarring, or loss of BRCA protein function. These assays can identify tumors with DNA-repair weakness beyond germline BRCA variants. They are not equivalent to inherited testing and have cancer-specific treatment uses.
Turnaround is commonly two to four weeks for germline panels, though urgent treatment testing can be faster. No fasting is required. The sample label, consent, clinical history, and family history should be complete because laboratories use this information during interpretation.
How to Interpret Test Results
Clinical laboratories use a five-tier system. The wording should be read exactly; “mutation” in casual conversation can blur important distinctions.
| Result category | Meaning | Usual action |
|---|---|---|
| Pathogenic | Strong evidence shows the variant disrupts gene function and causes increased cancer susceptibility. | Use gene-specific screening, prevention, treatment, and family testing. |
| Likely pathogenic | Evidence strongly favors a harmful effect, usually above 90% certainty. | Managed like a pathogenic variant in most clinical settings. |
| Variant of uncertain significance | Evidence is insufficient or conflicting. | Do not use alone for surgery, intensified screening, or predictive family testing. |
| Likely benign or benign | The variant is not considered a cause of hereditary cancer. | Base care on personal and family history, not this variant. |
| No pathogenic variant found | No reportable harmful change was detected by the assay. | Interpret as a true negative or uninformative negative depending on the family context. |
A true negative occurs when the family has a known pathogenic variant and the tested relative does not carry it. That person generally returns to population or history-based risk for BRCA-related cancers and cannot pass that familial variant to children.
An uninformative negative occurs when no family variant is known. It may mean there is no inherited predisposition, the family’s cause lies in another gene, current technology missed a variant, or cancer clustering occurred by chance. Screening may still be intensified based on family history.
A VUS is commoner with larger panels and in populations underrepresented in genetic databases. Most VUS findings are eventually downgraded, though some are upgraded. Medical decisions should rely on established risk factors while the classification is uncertain. Relatives are generally not offered predictive testing for a VUS outside a structured segregation study.
Variant classifications can change. Keep contact information current with the ordering clinic and laboratory, and ask who will notify the family if reclassification occurs. A reissued report should be reviewed before changing care.
Cancer Risks From Pathogenic Variants
Risk estimates are ranges because studies differ in age, ancestry, family selection, preventive surgery, and follow-up. GeneReviews estimates female breast cancer risk by age 70 at roughly 55%–72% for BRCA1 and 45%–69% for BRCA2. Ovarian cancer risk is about 39%–44% for BRCA1 and 11%–17% for BRCA2. Other large studies may report somewhat different age-80 estimates.
BRCA1-associated ovarian cancer tends to occur earlier than BRCA2-associated disease. This difference affects the recommended timing of risk-reducing salpingo-oophorectomy. Risk does not suddenly begin at one birthday; the age range reflects when benefit generally starts to outweigh the harms of premature menopause.
BRCA2 has a stronger association with male breast cancer, with estimated lifetime risk around 6%–8%, compared with roughly 1%–2% for BRCA1 and about 0.1% in the general male population. BRCA2 also substantially raises prostate cancer risk and is associated with earlier or more aggressive disease in some carriers.
Pancreatic cancer risk is increased with both genes, more clearly with BRCA2. Estimates are often around 1%–3% for BRCA1 and 3%–5% or higher for BRCA2, depending on age and family history. Screening recommendations have expanded but differ among organizations regarding whether a family history is required.
A person who has had one breast cancer remains at increased risk for a new cancer in the opposite breast. The risk depends on the gene, age at first cancer, treatment, and time since diagnosis. This can influence surgery and surveillance but does not mean bilateral mastectomy is mandatory.
BRCA2 may also be associated with melanoma, particularly in some families, but the magnitude is less certain than for breast, ovarian, prostate, or pancreatic cancer. Dermatologic surveillance is usually individualized to personal and family history.
No risk estimate predicts an individual’s future with certainty. A counselor may use models that incorporate family history, breast density, reproductive factors, polygenic modifiers, and prior biopsy findings to refine decisions beyond the gene average.
Screening and Risk Reduction
Women with a pathogenic BRCA1 or BRCA2 variant are generally offered annual breast MRI beginning around age 25 and annual mammography beginning around age 30, often alternating so some breast imaging occurs every six months. Exact starting ages depend on the guideline, prior radiation, family history, pregnancy, and local practice.
MRI is more sensitive than mammography in young dense breasts but produces more false positives and requires contrast. Mammography can detect calcifications that MRI may miss. Clinical breast awareness and prompt evaluation of a new mass, nipple change, or skin change remain important between scheduled studies.
Risk-reducing bilateral mastectomy can lower breast cancer risk by about 90% or more but does not reduce it to zero. It is an option, not a requirement. Decisions include current age, prior cancer, imaging burden, body image, reconstruction, surgical risks, breastfeeding plans, and personal values. Enhanced surveillance is a valid alternative for many carriers.
Ovarian screening with transvaginal ultrasound and CA-125 has not reliably detected early disease or reduced mortality. Risk-reducing bilateral salpingo-oophorectomy is the established prevention strategy after childbearing. Typical timing is age 35–40 for BRCA1 and age 40–45 for BRCA2, individualized to family history and health. The surgeon should follow a high-risk protocol with complete fallopian-tube examination.
Premenopausal ovary removal causes immediate menopause and can affect bone, heart, sexual, cognitive, and overall health. Menopausal hormone therapy may be appropriate for some carriers without a contraindication, especially those without prior breast cancer. Counseling should occur before surgery, not after symptoms begin.
Removing the fallopian tubes first and delaying ovary removal is under study. It may reduce some risk while postponing menopause, but its ability to prevent ovarian cancer as effectively as standard salpingo-oophorectomy is not yet fully established. Trial participation is preferable when available.
Pancreatic screening may use annual MRI/MRCP and/or endoscopic ultrasound, generally beginning around age 50 or ten years before the earliest family diagnosis. It should occur in experienced high-risk programs because incidental findings, uncertain lesions, and procedure risks require specialist management.
Men with BRCA2 variants are usually offered prostate screening from about age 40; BRCA1 carriers may also consider earlier screening. Male breast awareness and periodic clinical examination begin in adulthood, with mammography considered for selected men based on breast tissue and family history.
Treatment Implications
BRCA status can influence local and systemic cancer treatment, but recommendations remain disease- and stage-specific. A pathogenic variant may affect surgical choices after breast cancer because of contralateral risk. Breast-conserving therapy can still be appropriate for many carriers; the gene does not automatically require mastectomy.
Tumors with BRCA1 or BRCA2 loss may be sensitive to platinum chemotherapy and PARP inhibitors because both exploit defective homologous recombination. PARP inhibitors are approved in selected breast, ovarian, prostate, and pancreatic cancer settings. Eligibility depends on the gene, germline or somatic status, stage, prior treatment, hormone-receptor or HER2 status, and the specific drug label.
For high-risk, HER2-negative early breast cancer with a germline pathogenic variant, adjuvant olaparib can reduce recurrence risk after appropriate local therapy and chemotherapy when clinical criteria are met. In metastatic HER2-negative breast cancer, germline BRCA status can identify PARP inhibitor options.
In ovarian cancer, germline and somatic BRCA findings can support PARP inhibitor maintenance, although indications have evolved as survival and toxicity data matured. Treatment should follow the current label and oncology guideline rather than an old report or general statement that all BRCA-positive ovarian cancers receive the same maintenance.
In metastatic castration-resistant prostate cancer, BRCA1/2 alterations can identify benefit from PARP-targeted strategies. BRCA2 tumors often show the strongest signal. Pancreatic cancer with a germline BRCA1/2 variant may be treated with platinum-based chemotherapy, and selected patients whose metastatic disease has not progressed can receive maintenance olaparib.
A positive result can also support clinical-trial eligibility. Resistance may develop through restoration of BRCA function, drug-efflux changes, replication-fork protection, or other mechanisms. A later tumor or liquid biopsy may help in selected cases, but routine resistance testing is not required in every progression.
Treatment choices must account for anemia, low platelets, kidney or liver function, pregnancy, drug interactions, prior cancers, and the small risk of therapy-related myeloid neoplasms with some DNA-damaging treatments. The molecular result creates options but does not replace oncology assessment.
Family Testing, Reproductive Options, and Limitations
Once a pathogenic variant is found, adult blood relatives can have targeted testing for the exact familial change. This is called cascade testing. Parents, siblings, and children each may have a 50% chance, while risk for more distant relatives depends on which side of the family carries the variant.
A clear family letter should include the gene, exact variant, laboratory, report date, and how relatives can access genetic counseling. Sharing the actual report prevents testing for the wrong spelling or relying on the vague phrase “the BRCA gene runs in our family.”
Reproductive options include natural conception with testing during pregnancy, in vitro fertilization with preimplantation genetic testing for the familial variant, donor eggs or sperm, adoption, or choosing not to test embryos. These are personal choices. Counseling should discuss success rates, cost, timing, emotional burden, and the fact that a carrier may never develop cancer.
Testing has technical limits. Deep intronic changes, complex rearrangements, low-level mosaicism, or variants not recognized as harmful may be missed. Laboratories also differ in RNA analysis and deletion coverage. A strong unexplained family history may justify updated testing after several years.
Privacy and discrimination rules depend on country. Before testing, people may wish to review life, disability, and long-term-care insurance considerations. Results can also create family tension when relatives differ in whether they want to know. Genetic counselors can support communication without pressuring anyone.
Questions to ask after receiving a report include:
- Is the variant pathogenic, likely pathogenic, or uncertain?
- Was full sequencing plus deletion/duplication analysis performed?
- Is this germline, tumor-only, or confirmed in both?
- What are my age-specific cancer risks?
- Which screening should begin now?
- What prevention options fit my reproductive and health plans?
- Which relatives should receive targeted testing?
- Does the result change current cancer treatment?
- Who will handle future variant reclassification?
Urgent medical care is not required simply because a pathogenic variant is found. New breast or abdominal symptoms, unexplained bleeding, jaundice, a testicular or breast mass in a man, or treatment complications should be evaluated promptly. Prevention works best through a planned high-risk program rather than panic-driven testing or surgery.
References
- BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer 2025 (Review)
- BRCA Gene Changes: Cancer Risk and Genetic Testing 2024
- Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline 2024 (Guideline)
- Ovarian cancer: identifying and managing familial and genetic risk 2024 (Guideline)
- BRCA1, BRCA2 and Associated Cancer Risks and Management for Male Patients: A Review 2024 (Review)
- BRCA1 or BRCA2 – risk management (female) 2025 (Guideline)
Disclaimer
This article is educational and does not replace genetic counseling, individualized cancer-risk assessment, or treatment advice. BRCA1 and BRCA2 results must be interpreted by variant classification, germline versus tumor origin, personal and family history, age, prior cancer, reproductive plans, and current guidelines. Do not use a VUS as the basis for preventive surgery or family predictive testing.
